Matthew Welch, MD
Retina Specialist · Phoenix, AZNPI 1316100977
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), other and ownership interests — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by US Retina LLC at 52.9% of the total. Reporting peaked in 2024 at $6,711 and has fallen 94.6% since, to $359 in 2025.
Across 110 payments — averaging $141.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$8K
- Alimera Sciences, Inc.$4K
- Regeneron Healthcare Solutions, Inc.$964
- Bausch & Lomb Americas Inc.$795
- AbbVie$484
- Genentech USA, Inc.$406
- plus $1K from 13 others
What the payments were for
- Food & beverage$7,31047%
- Education$270%
- Ownership interest$3,23821%
- Other$5,00032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $8,238 |
| Alimera Sciences, Inc. | 10 | $3,649 |
| Regeneron Healthcare Solutions, Inc. | 26 | $964 |
| Bausch & Lomb Americas Inc. | 10 | $795 |
| AbbVie(2 entities) | 18 | $484 |
| Genentech USA, Inc. | 15 | $406 |
| Genentech, Inc. | 2 | $220 |
| Eyepoint US, Inc. | 3 | $166 |
| Novartis | 4 | $141 |
| Dutch Ophthalmic, USA | 1 | $131 |
| Apellis Pharmaceuticals, Inc. | 4 | $82 |
| Coherus Oncology, Inc. | 3 | $81 |
| Alcon | 1 | $57 |
| Mallinckrodt Hospital Products Inc. | 1 | $40 |
| Sun Pharmaceutical Industries Inc. | 1 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Lumibird Medical Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$3,345
- YUTIQ$981
- STELLARIS$485
- EYLEA HD$274
- STELLARIS ELITE$182
- EVA Ophthalmic Surgical System$131
- SUSVIMO$123
- VABYSMO$123
- OZURDEX$102
How this compares
$15,576 in reported general payments places this provider in the 55th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 226 | $10,407 |
| Brimonidine Tartrate | 73 | $2,620 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 150 | $2,338 |
| Ofloxacin | 198 | $2,230 |
| Latanoprost | 214 | $2,168 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,249 |
| Difluprednate | 13 | $704 |
| Timolol Maleate | 37 | $452 |
| Dorzolamide Hcl | 16 | $329 |
| Acyclovir | 13 | $316 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Alan GordonPhoenix$86K
- Suhail AlamPhoenix$24K
- Rima PatelPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.